The honest answer on microdosing is that the controlled trials don’t show much, the open-label data shows a lot, and the difference between those two things is mostly placebo. Which doesn’t mean nothing’s happening, it means what’s happening is mostly the kind of thing that happens any time you take a substance you really believe is going to change your life… which is its own real effect, just not the effect people think they’re paying for.
What we even mean by microdosing
Roughly one-tenth of a recreational dose of a psychedelic, taken on an intermittent schedule, with the explicit intent that you don’t actually feel high. The two most common protocols are the Fadiman one (one day on, two days off, repeating) and the Stamets stack (psilocybin plus lion’s mane and a flushing dose of niacin, on a four-on-three-off cycle). You aren’t supposed to feel altered. You’re supposed to feel slightly better, slightly clearer, for a long time, on a schedule that doesn’t disrupt your work or your driving.
Most microdosing in the wild is psilocybin (the active compound in psychedelic mushrooms) or LSD. A smaller but growing number of guys are using DMT (a faster-acting compound that has to be smoked or dosed sublingually) or 1P-LSD (a research-chemical cousin of LSD that’s legally ambiguous in some jurisdictions) or whatever else is moving through the unregulated supply right now. The compounds vary. The protocols vary. The dose accuracy varies a lot, especially with mushrooms, because the alkaloid content of dried mushrooms varies sample to sample even from the same grower, and most people doing this aren’t running their stuff through a lab.
What the open-label data shows
The self-report studies are pretty consistent and pretty impressive looking. People microdosing report improved mood, better focus, reduced anxiety, more creativity, improved sleep, and generally feeling like a slightly better version of themselves. The effect sizes in those studies are big. If you took the open-label numbers at face value, microdosing would be the most important psychiatric intervention developed in twenty years and we’d all be writing a different kind of post about it.
The problem is that open-label means everyone in the study knew they were taking the thing. There’s no comparison group taking something inert. And people who choose to microdose are not a random sample of the population… they’re people who already believe the intervention is going to help them, who’ve sought it out, often paid for it, often gotten it from a friend they trust, who’ve read the protocols, who’ve built rituals around it, and who are pre-committed to the outcome. That’s basically the worst possible study design for separating actual drug effect from everything else around it.
What the controlled trials actually show
When you put microdosing up against placebo in a properly blinded design (where neither the participant nor the person running the study knows who got the real one), the gap mostly closes. The Szigeti study out of Imperial College London in 2021 ran a clever self-blinded design where participants didn’t know if they were taking real microdoses or placebo, and the differences on most outcomes were small or not statistically significant. The people who took real microdoses did marginally better on some measures. They also did much better on what they expected the doses would do, which is most of the effect right there.
A handful of smaller placebo-controlled trials on LSD microdosing in healthy adults have shown changes in some cognitive metrics and mood measures that are statistically detectable, but the effect sizes are modest and the clinical meaning is uncertain. The depression and anxiety endpoints in particular have not separated from placebo in a way that would justify recommending microdosing as a real treatment for either condition. Anybody telling you the controlled data supports microdosing as therapy for depression is, if we’re being honest, a damn liar or hasn’t read the trials.
The full-dose psychedelic-assisted therapy literature, where you give somebody a real psychedelic dose plus a session with a therapist, is a completely separate thing, and that literature actually does have signal, particularly for depression and PTSD (post-traumatic stress disorder, the trauma-driven anxiety condition with the flashbacks-and-hypervigilance pattern). Microdosing and one-big-trip-with-a-therapist are not the same intervention, and conflating them is one of the louder things people do on the internet about this topic.
The legal piece, because OR/WA is unusual
Oregon’s Measure 109 created a regulated framework for supervised psilocybin use at licensed service centers, not for microdosing at home. The service centers are dosing in the macro range with a facilitator in the room. The cost is steep, the waitlists are real, and it isn’t covered by anyone’s insurance. Microdosing at home is still illegal under federal law and almost everywhere under state law, including in Oregon. Possession of psilocybin in Oregon was briefly decriminalized under Measure 110 in 2020 and then partially recriminalized in 2024, with possession of small amounts turning back into a Class E violation with a fine in most contexts. In Washington it’s still a misdemeanor outside of Seattle, where the Seattle Police Department has a stated deprioritization policy that isn’t quite legalization.
The practical reality is that a lot of guys microdose anyway and enforcement against personal use is basically zero. The legal risk is real but small. The bigger risks are supply (knowing what’s actually in what you bought), dose accuracy (especially with mushrooms), and the slow-creeping problem of building your mood around a substance you can’t reliably source.
What’s nice to hear, since most of this post has been about the data being weak
People who start microdosing often report feeling meaningfully better, and even if most of that effect is placebo and ritual and the lifestyle changes that tend to accompany it, the feeling-better part is still real to them. Placebo isn’t fake. Placebo is the part of any treatment that comes from the ritual of taking the treatment seriously, and that part has measurable effects on mood, sleep, and pain in study after study. The fact that microdosing isn’t separating from placebo means a meaningful chunk of the effect is from the placebo side of the equation, which is still effect. If somebody’s life is better and the worst-case scenario is they spent some money on the wrong intervention, that’s not the worst outcome we’ve ever seen.
The version where this becomes a clinical problem is when somebody on a real antidepressant decides the mushrooms are doing the work and stops the antidepressant. The drug doesn’t suddenly stop working when you decide it isn’t doing anything… it just keeps doing things you stopped attributing to it, and then when the antidepressant clears the system three weeks later the depression comes back and now the person is convinced both the medication failed and the mushrooms failed, when actually neither one really failed.
The pattern, in shape
The kind of guy who shows up in an appointment is usually somebody with a long-standing mild-to-moderate depression who’s been on Wellbutrin (bupropion, a dopamine and norepinephrine antidepressant) for a few years with decent but incomplete response. He starts microdosing psilocybin from a friend’s homegrown stash, one day on two days off, for a few months. Feels great. Comes in to ask whether he can drop the Wellbutrin now that the mushrooms are clearly doing the work.
The question that matters is, what else changed when you started the mushrooms. The honest answer is usually a lot of things. He also started going to the gym a few times a week. Joined a small group of friends who were also microdosing and started meeting them for hikes on weekends, which means more sunlight, more aerobic exercise, and more actual friend time than he’d been getting. He stopped drinking on weeknights because he wanted to take the microdosing protocol seriously and didn’t want alcohol confusing it. He started sleeping better because of all of the above.
So which part of that is doing the work. Probably some of it is the microdose. Probably more of it is the gym and the friends and the sleep and not drinking on Tuesday. The mushrooms are getting credit for the lifestyle, partly because the lifestyle came along with the mushrooms. The right move is usually to keep doing everything that’s working, including the Wellbutrin, and stop trying to figure out which single variable is the magic one, because life isn’t a controlled trial and the parts that work usually work together.
If you took the open-label numbers at face value, microdosing would be the most important psychiatric intervention developed in twenty years. Then you blind the study and most of the effect goes away.
Bottom line
The controlled data does not support microdosing as a standalone treatment for depression or anxiety. The lived experience of a lot of people who do it is positive, and most of that is placebo, ritual, and the lifestyle changes that tend to come with deciding to take your mental health seriously enough to plan a protocol around it. None of that is bad. Just don’t drop your antidepressant for it, don’t get your supply from somebody you wouldn’t trust to watch your kid, and don’t decide what’s working before you’ve isolated which variable changed. Most of the people doing well on this aren’t doing well because of the molecule. They’re doing well because deciding to microdose was the version of “I’m going to start taking this seriously” that finally stuck.
Sources
- Szigeti B, Kartner L, Blemings A, et al. Self-blinding citizen science to explore psychedelic microdosing. Elife. 2021;10:e62878. PMID 33648632.
- Polito V, Stevenson RJ. A systematic study of microdosing psychedelics. PLoS One. 2019;14(2):e0211023. PMID 30726251.
- Carhart-Harris RL, Goodwin GM. The Therapeutic Potential of Psychedelic Drugs. Neuropsychopharmacology. 2017;42(11):2105-2113. PMID 28443617.